Microvascular Therapeutics is a clinical stage biotechnology which pioneers in ultrasound contrast agents and theranostics. Microvascular Therapeutics (MVT) is developing a new improved ultrasound contrast agent MVT-100 via the 505(b)(2) pathway. The founders of MVT developed Definity®, the world’s #1 selling ultrasound contrast agent. Definity requires refrigerated temperature storage and has side effect of back pain. MVT-100 is a room temperature storage product and designed to eliminate the back pain. MVT has multiple theranostic products in its pipeline with multi-billion dollar market potential, the first one of which is expected to be regulated via the device pathway.
Company Details
- Employees
- 13
- Founded
- 2009
- Address
- 1635 E 18th St, Tucson,arizona 85719,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- mvtpharma.com
- HQ
- Tucson, Arizona
Microvascular Therapeutics Questions
Microvascular Therapeutics's website is mvtpharma.com
Microvascular Therapeutics's LinkedIn profile is https://www.linkedin.com/company/microvascular-therapeutics-llc
Microvascular Therapeutics has
13 employees.
View email and phone details for 13
employees at Microvascular Therapeutics.
Microvascular Therapeutics's industry is
Biotechnology Research
Microvascular Therapeutics's top competitors are
Inanobio,
Immuto Scientific,
Echo Iq (Asx:eiq),
Atom Bioworks,
Az Sint-Blasius,
Cordance Medical,
Nuvox Therapeutics,
Ceria Therapeutics,
Artery Therapeutics, Inc.,
Codexis, Inc..
Microvascular Therapeutics's categories are Biotechnology Research
Microvascular Therapeutics's founding year is 2009
